A5040164000- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Aortic Disease and Treatment Approaches
- Coronary Interventions and Diagnostics
- Cardiomyopathy and Myosin Studies
- Cardiac pacing and defibrillation studies
- Vascular Procedures and Complications
- Cardiac Arrhythmias and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Effects of Exercise
- Lipoproteins and Cardiovascular Health
- Cardiac Structural Anomalies and Repair
- Peripheral Artery Disease Management
- Acute Myocardial Infarction Research
- Orthopedic Infections and Treatments
- Aortic aneurysm repair treatments
- Cardiac tumors and thrombi
- Cancer, Lipids, and Metabolism
- Cardiac and Coronary Surgery Techniques
- Venous Thromboembolism Diagnosis and Management
- Aortic Thrombus and Embolism
- Eosinophilic Disorders and Syndromes
- Atrial Fibrillation Management and Outcomes
Heart and Diabetes Center North Rhine-Westphalia
2016-2025
Ruhr University Bochum
2015-2019
Heidelberg University
2017
New-onset conduction disturbances still represent a considerable problem after transcatheter aortic valve implantation (TAVI). The aim of this study was to identify calcification patterns with an elevated risk for permanent pacemaker (PPI) TAVI and investigate underlying mechanisms in ex vivo setting. One hundred sixty-two patients who underwent the Edwards SAPIEN XT® or Medtronic CoreValve® at our institution were analysed. calcium load device landing zone quantified 3mensio®, PPI...
Background: Few randomized trials have compared bioprostheses for transcatheter aortic valve replacement, and no with supra-annular design. The SCOPE 2 trial (Safety Efficacy Comparison of Two TAVI Systems in a Prospective Randomized Evaluation 2) was designed to compare the clinical outcomes ACURATE neo CoreValve Evolut replacement. Methods: performed at 23 centers 6 countries between April 2017 2019. Patients ≥75 years old an indication transfemoral replacement as agreed by heart team were...
Peri-procedural transcatheter valve embolization and migration (TVEM) is a rare but potentially devastating complication of aortic implantation (TAVI). We sought to assess the incidence, causes, outcome TVEM in large multicentre cohort.We recorded cases peri-procedural patients undergoing TAVI between January 2010 December 2017 from 26 international sites. occurred 273/29 636 (0.92%) (age 80.8 ± 7.3 years; 53.8% female), which 217 were ascending aorta 56 left ventricle. The use...
Life-threatening complications occur during transcatheter aortic valve implantation (TAVI) which can require emergent cardiac surgery (ECS). Risks and outcomes of patients needing ECS or immediately after TAVI are still unclear.Incidence, risk factors, management, requiring transfemoral (TF)-TAVI were analysed from a contemporary real-world multicentre registry. Between 2013 2016, 27 760 underwent TF-TAVI in 79 centres. Of these, 212 (0.76%) required (age 82.4 ± 6.3 years, 67.5% females,...
AimsCalcification of the device landing zone is linked to paravalvular regurgitation after transcatheter aortic valve implantation (TAVI). The mechanisms remain incompletely understood and performance next-generation heart valves (THV) has not been investigated. We evaluated impact calcification patterns on residual (AR) TAVI with different THV in patients severe stenosis.
Vascular access site complications are associated with increased morbidity and mortality after transcatheter aortic valve implantation (TAVI). Current results comparing strategies plug- (P-VCD; MANTA) suture-based vascular closure devices (S-VCD; Perclose ProGlide) remain inconsistent. It was our aim to assess the incidence of access-related P-VCD or S-VCD transfemoral TAVI. The Plug sUture based vascuLar cloSurE TAVI (PULSE) registry retrospectively evaluated 10,120 consecutive patients who...
Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. This study evaluates real-world experience with mavacamten, focusing on maintenance dose determination to optimise individual therapy enhance patient safety. 36 patients oHCM who completed initiating phase of mavacamten were analysed. CYP2C19 genetic testing determined metabolic status prior...
Abstract Background and aims Prosthetic valve endocarditis (PVE) is the prognostically most unfavourable complication after aortic replacement. This study to contribute a better understanding of different pathological therapeutical aspects between PVE following surgical (SAVR) transcatheter replacement (TAVI). Methods All patients who had undergone primary isolated SAVR ( n = 3447) or TAVI 2269) at our Centre 01/2012 12/2018 were analysed. Diagnosis was based on Duke criteria modified in...
Objective Residual paravalvular regurgitation (PVR) has been associated to adverse outcomes after transcatheter aortic valve replacement (TAVR). This study sought evaluate the impact of device landing zone (DLZ) calcification on residual PVR TAVR with different next-generation heart valves. Methods 642 patients underwent a SAPIEN 3 (S3; n=292), ACURATE neo (NEO; n=166), Evolut R (ER; n=132) or Lotus (n=52). Extent, location and asymmetry DLZ were assessed from contrast-enhanced CT imaging...
The Academic Research Consortium - High Bleeding Risk (ARC-HBR) initiative defined conditions associated with percutaneous coronary intervention (PCI)-related bleeding.
The number of implanted biological valves for treatment valvular heart disease is growing and a percentage these patients will eventually undergo transcatheter valve-in-valve (ViV) procedure. Some represent challenging cases. aim this study was to develop feasible algorithm plan in vitro simulate new interventional procedure improve patient outcome.In addition standard diagnostic routine, our includes 3D printing the annulus, hydrodynamic measurements high-speed analysis leaflet kinematics...
BackgroundNo detailed data on left bundle branch block (LBBB) and permanent pacemaker implantation (PPI) exist from randomized clinical trials comparing the ACURATE neo CoreValve Evolut (Evolut) devices. AimsTo assess incidence impact of new LBBB PPI with self-expanding prostheses a powered comparison. MethodsFrom SCOPE 2 trial, 648 patients without previous were analysed for at 30 days, 426 adopted analysis days. ResultsAt 16.5% required PPI; rates higher in compared to recipients (21.0%...
Hypertrophic cardiomyopathy is the most common genetic cardiac disease and characterized by left ventricular hypertrophy. Although this hypertrophy often associates with sarcomeric gene mutations, nongenetic factors also contribute to disease, leading diastolic dysfunction. Notably, dysfunction manifests before linked hypercontractility, as well nonuniform contraction relaxation (myofibril asynchrony) of myocardium. distribution in hypertrophic can vary both between within individuals,...
Evaluation of the impact sheath diameter on vascular complications and mortality in transfemoral aortic valve implantation.Between 2012 2014, 183 patients underwent procedure using a 18-24 F. This collective was divided into two groups: group 1, with 18F (G1, n = 94), consisted Medtronic Sentrant 18 F Direct Flow sheaths, 2 19-24 (G2, 89) Edwards expandable e-sheath Solopath sheaths. Perclose-Proglide® used as closure device all patients.G1 had significantly more female (64.9% vs. 46.1% G2,...
Objectives We present our single center experience with Medtronic CoreValve and Evolut R regarding procedural outcome 3 years follow‐up in patients degenerated bioprostheses. Methods From 1645 who underwent transfemoral TAVI at institution between February 2009 December 2016, 37 bioprosthesis were treated CoreValve/Evolut R. All data concerning baseline characteristic, outcomes entered into a dedicated database. Results Mean age was 83.9 ± 4.4 showed an average logistic EuroSCORE of 33.2...
Aims: Our aim was to assess the clinical outcomes of Direct Flow Medical Transcatheter Aortic Valve System (DFM-TAVS), when used in routine practice.Methods and results: This is a prospective, open-label, multicentre, post-market registry patients treated with DFM-TAVS according approved commercial indications.Echocardiographic angiographic data were evaluated by an independent core laboratory adverse events adjudicated classified VARC-2 criteria committee.The primary endpoint freedom from...
Background: Treatment of severely calcified aortic valve stenosis is associated with a higher rate paravalvular leakage (PVL) and permanent pacemaker implantation (PPI). We hypothesized that the self-expanding transcatheter heart (THV) prostheses Evolut Pro (EPro) comparable to balloon-expandable Sapien 3 (S3) regarding hemodynamics, PPI, clinical outcome in these patients. Methods: From 2014 2019, all patients very severe calcification who received an EPro or S3 THV were included....
The aim of this study was to determine the best functional position a transcatheter heart valve (THV) implanted as valve-in-valve (ViV) procedure in small rapid deployment valves (RDV) an vitro model.A 21 mm Perceval, Enable or INTUITY RDV mounted into pulse duplicator and 23 balloon-expandable self-expanding THV deployed (valve-in-valve) two different positions. Under physiological hydrodynamic conditions, performance characterised by mean transvalvular pressure gradient (MPG), effective...